The DOI matches its Crossref record; 882 of the 882 references it cites were found in a registry or an index.
Cold and hot tumors: from molecular mechanisms to targeted therapy
Open accessAbstract
Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which has shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment in cancer therapy, only a minority of patients exhibit a positive response to it. In patients with solid tumors, those who respond well to ICB treatment typically demonstrate an active immune profile referred to as the “hot” (immune-inflamed) phenotype. On the other hand, non-responsive patients may exhibit a distinct “cold” (immune-desert) phenotype, differing from the features of “hot” tumors. Additionally, there is a more nuanced “excluded” immune phenotype, positioned between the “cold” and “hot” categories, known as the immune “excluded” type. Effective differentiation between “cold” and “hot” tumors, and understanding tumor intrinsic factors, immune characteristics, TME, and external factors are critical for predicting tumor response and treatment results. It is widely accepted that ICB therapy exerts a more profound effect on “hot” tumors, with limited efficacy against “cold” or “altered” tumors, necessitating combinations with other therapeutic modalities to enhance immune cell infiltration into tumor tissue and convert “cold” or “altered” tumors into “hot” ones. Therefore, aligning with the traits of “cold” and “hot” tumors, this review systematically delineates the respective immune characteristics, influencing factors, and extensively discusses varied treatment approaches and drug targets based on “cold” and “hot” tumors to assess clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–800 of 882
Cascone, T., Kar, G., Spicer, J. D., García-Campelo, R., Weder, W., Daniel, D. B., Spigel, D. R., Hussein, M., Mazières, J., Oliveira, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0436 · Cited by 161
Nanoparticle‐Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
Nuhn, L., De Koker, S., Van Lint, S., Zhong, Z., Catani, J. P., Combes, F., Deswarte, K., Li, Y., Lambrecht, B. N., Lienenklaus, S., et al. (2018) · Advanced Materials · doi:10.1002/adma.201803397 · Cited by 159
Jiang, L., Fang, X., Wang, H., Li, D., & Wang, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02927 · Cited by 159
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
Hsu, Y.-L., Hung, J.-Y., Chiang, S.-Y., Jian, S.-F., Wu, C.-Y., Lin, Y.-S., Tsai, Y.-M., Chou, S.-H., Tsai, M.-J., & Kuo, P.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.8488 · Cited by 158
Macrophages are metabolically heterogeneous within the tumor microenvironment
Geeraerts, X., Fernández-García, J., Hartmann, F. J., de Goede, K. E., Martens, L., Elkrim, Y., Debraekeleer, A., Stijlemans, B., Vandekeere, A., Rinaldi, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110171 · Cited by 158
Duhen, R., Ballesteros‐Merino, C., Frye, A. K., Tran, E., Rajamanickam, V., Chang, S., Koguchi, Y., Bifulco, C. B., Bernard, B. M., Leidner, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21383-1 · Cited by 156
Chen, D., Verma, V., Patel, R. R., Barsoumian, H. B., Cortez, M. A., & Welsh, J. W. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.032 · Cited by 155
Mondini, M., Loyher, P.-L., Hamon, P., de Thoré, M. G., Laviron, M., Berthelot, K., Clémenson, C., Salomon, B. L., Combadière, C., Deutsch, É., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0633 · Cited by 154
Ma, Y., Li, J., Wang, H., Chiu, Y., Kingsley, C. V., Fry, D., Delaney, S. N., Wei, S. C., Zhang, J., Maitra, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.018 · Cited by 154
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
Mender, I., Zhang, A., Ren, Z., Han, C., Deng, Y., Siteni, S., Li, H., Zhu, J., Vemula, A., Shay, J. W., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.020 · Cited by 154
Sholler, G. L. S., Gerner, E. W., Bergendahl, G., MacArthur, R. B., VanderWerff, A., Ashikaga, T., Bond, J. P., Ferguson, W. S., Roberts, W. D., Wada, R. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127246 · Cited by 152
Diggs, L. P., Ruf, B., Ma, C., Heinrich, B., Cui, L., Zhang, Q., McVey, J. C., Wabitsch, S., Heinrich, S., Rosato, U., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.037 · Cited by 151
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Catani, J. P. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 149
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Aznar, M. A., Planelles, L., Pérez‐Olivares, M., Molina, C., Garasa, S., Etxeberría, I., Pérez, G., Rodríguez, I., Bolaños, E., Lopez-Casas, P. P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0568-2 · Cited by 149
Tenascin-C Protects Cancer Stem–like Cells from Immune Surveillance by Arresting T-cell Activation
Jachetti, E., Caputo, S., Mazzoleni, S., Brambillasca, C. S., Parigi, S. M., Grioni, M., Piras, I. S., Restuccia, U., Calcinotto, A., Freschi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2346 · Cited by 147
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 146
Evolution of delayed resistance to immunotherapy in a melanoma responder
Liu, D., Lin, J., Robitschek, E. J., Kasumova, G. G., Heyde, A., Shi, A., Kraya, A., Zhang, G., Moll, T. O. C., Frederick, D. T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01331-8 · Cited by 146
Functional reprogramming of regulatory T cells in the absence of Foxp3
Charbonnier, L.-M., Cui, Y., Stephen-Victor, E., Harb, H., Lopez, D., Bleesing, J. J., Garcia-Lloret, M. I., Chen, K., Ozen, A., Carmeliet, P., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0442-x · Cited by 145
Xue, Y., Lu, F., Chang, Z., Li, J., Gao, Y., Zhou, J., Luo, Y., Lai, Y., Cao, S., Li, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40518-0 · Cited by 145
de Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., Ommen, H. B., Семочкин, С. В., Kim, H., Larson, R. A., et al. (2022) · Blood · doi:10.1182/blood.2021014901 · Cited by 143
Martínez, D., Vermeulen, M. E., Trevani, A. S., Ceballos, A., Sabatté, J., Gamberale, R., Álvarez, M. E., Salamone, G. V., Tanos, T., Coso, O. A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.1163 · Cited by 142
Frankenberger, C. A., Rabe, D. C., Bainer, R. O., Sankarasharma, D., Chada, K. K., Krausz, T. N., Gilad, Y., Becker, L., & Rosner, M. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3394 · Cited by 142
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities
Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 141
Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity
Giampazolias, E., Schulz, O., Lim, K. H. J., Rogers, N. C., Chakravarty, P., Srinivasan, N., Gordon, O., Cardoso, A., Buck, M. D., Poirier, E. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.021 · Cited by 141
Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery
Lin, D., Feng, X., Mai, B., Li, X., Wang, F., Liu, J.-X., Liu, X., Zhang, K., & Wang, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121124 · Cited by 141
Makharadze, T., Gogishvili, M., Melkadze, T., Baramidze, A., Giorgadze, D., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.008 · Cited by 140
Yuan, S., Nie, R., Jin, Y., Liang, C., Li, Y., Jian, R., Sun, X., Chen, Y.-B., Guan, W., Wang, Z., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02721-w · Cited by 140
Wong, K. M., Horton, K. J., Coveler, A. L., Hingorani, S. R., & Harris, W. P. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0608-3 · Cited by 139
Razak, A. R., Cleary, J. M., Moreno, V., Boyer, M. J., Calvo, E., Edenfield, W. J., Tie, J., Harvey, R. D., Rutten, A., Shah, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001006 · Cited by 138
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
Lou, X., Chen, Z., He, Z., Sun, M., & Sun, J. (2021) · Nano-Micro Letters · doi:10.1007/s40820-020-00560-9 · Cited by 138
Gargaro, M., Scalisi, G., Manni, G., Briseño, C. G., Bagadia, P., Durai, V., Theisen, D. J., Kim, S. K., Castelli, M., Xu, C. A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.013 · Cited by 138
Epigenetic regulation in cancer
Gu, M., Ren, B., Fang, Y., Ren, J., Liu, X., Wang, X., Zhou, F., Xiao, R., Luo, X., You, L., et al. (2024) · MedComm · doi:10.1002/mco2.495 · Cited by 138
Mesenchymal stem cells: From regeneration to cancer
Li, P., Gong, Z., Shultz, L. D., & Ren, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.005 · Cited by 137
ABCC1 transporter exports the immunostimulatory cyclic dinucleotide cGAMP
Maltbaek, J. H., Cambier, S., Snyder, J. M., & Stetson, D. B. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.006 · Cited by 137
Microbiome signatures in prostate cancer
Banerjee, S., Alwine, J. C., Wei, Z., Tian, T., Shih, N. N. C., Sperling, C. D., Guzzo, T. J., Feldman, M. D., & Robertson, E. S. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz008 · Cited by 135
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis
Mashreghi, M., Azarpara, H., Bazaz, M. R., Jafari, A., Masoudifar, A., Mirzaei, H., & Jaafari, M. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26049 · Cited by 133
Concepcion, A. R., Wagner, L. E., Zhu, J., Tao, A. Y., Yang, J. J. J., Khodadadi‐Jamayran, A., Wang, Y., Liu, M., Rose, R. E., Jones, R., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01105-x · Cited by 133
Matias, M. I., Yong, C. S. M., Foroushani, A. B. K., Goldsmith, C., Mongellaz, C., Sezgin, E., Levental, K. R., Talebi, A., Perrault, J., Riviere, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109911 · Cited by 132
Murakami, M., Ernsting, M. J., Undzys, E., Holwell, N., Foltz, W. D., & Li, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0062 · Cited by 131
Asah2 Represses the p53–Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis
Zhu, H., Klement, J. D., Lu, C., Redd, P. S., Yang, D., Smith, A. D., Poschel, D. B., Zou, J., Liu, D., Wang, P. G., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000500 · Cited by 130
Fucà, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004001 · Cited by 129
Molecular mechanisms of CD8+ T cell trafficking and localization
Nolz, J. C. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1835-0 · Cited by 129
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Musella, M., Guarracino, A., Manduca, N., Galassi, C., Ruggiero, E., Potenza, A., Maccafeo, E., Manic, G., Mattiello, L., Rehim, S. S. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01290-3 · Cited by 129
Watts, J. M., Baer, M. R., Yang, J., Prébet, T., Lee, S., Schiller, G. J., Dinner, S. N., Pigneux, A., Montesinos, P., Wang, E. S., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00292-7 · Cited by 129
Liu, M., Thomas, S. L., DeWitt, A. K., Zhou, W., Madaj, Z. B., Ohtani, H., Baylin, S. B., Liang, G., & Jones, P. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3953 · Cited by 127
Collagen Density Modulates the Immunosuppressive Functions of Macrophages
Larsen, A. M. H., Kuczek, D. E., Kalviša, A., Siersbæk, M. S., Thorseth, M., Johansen, A. Z., Carretta, M., Grøntved, L., Vang, O., & Madsen, D. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900789 · Cited by 127
Guo, J., May, H. D., Franco, S., Noureddine, A., Tang, L., Brinker, C. J., Kusewitt, D. F., Adams, S. F., & Serda, R. E. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00795-w · Cited by 127
Zhang, B., Qi, L. Y., Wang, X., Xu, J., Liu, Y., Mu, L., Wang, X., Bai, L., & Huang, J. (2020) · 癌症:英文版 · doi:10.1002/cac2.12119 · Cited by 126
Self-citation12/15-lipoxygenase–mediated enzymatic lipid oxidation regulates DC maturation and function
Rothe, T., Грубер, Ф., Uderhardt, S., Ipseiz, N., Rößner, S., Oskolkova, O., Blüml, S., Leitinger, N., Bicker, W., Bochkov, V. N., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78490 · Cited by 123
Ascierto, P. A., Stroyakovskiy, D., Gogas, H. J., Robert, C., Lewis, K. D., Protsenko, S. A., Pereira, R. P., Eigentler, T., Rutkowski, P. L., Демидов, Л. В., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00687-8 · Cited by 123
Tian, L., Yi, X., Dong, Z., Xu, J., Liang, C., Chao, Y., Wang, Y., Yang, K., & Liu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b06699 · Cited by 122
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 120
Yang, J., Yan, C. W., Vilgelm, A. E., Chen, S., Ayers, G. D., Johnson, C. A., & Richmond, A. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0312 · Cited by 120
Chung, A. W., Anand, K., Anselme, A. C., Chan, A. A., Gupta, N., Venta, L. A., Schwartz, M. R., Qian, W. P., Xu, Y., Zhang, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5070 · Cited by 120
Siddiqui, I., Erreni, M., van Brakel, M., Debets, R., & Allavena, P. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0125-1 · Cited by 119
Vinogradov, A. A., & Suga, H. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.003 · Cited by 119
Tse, S., McKinney, K. M., Walker, W., Nguyen, M., Iacovelli, J., Small, C. G., Hopson, K., Zaks, T. Z., & Huang, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.002 · Cited by 119
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 119
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Li, G., Zhao, X., Zheng, Z., Zhang, H., Wu, Y., Shen, Y., & Chen, Q. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05191-6 · Cited by 119
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Au, K. M., Park, S. I., & Wang, A. Z. (2020) · Science Advances · doi:10.1126/sciadv.aba8564 · Cited by 118
Waldhauer, I., Gonzalez‐Nicolini, V., Freimoser–Grundschober, A., Nayak, T. K., Fahrni, L., Hosse, R. J., Gerrits, D., Geven, E. J., Sam, J., Lang, S., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1913791 · Cited by 118
Haag, G. M., Springfeld, C., Grün, B., Apostolidis, L., Zschäbitz, S., Dietrich, M., Berger, A.-K., Weber, T. F., Zoernig, I., Schaaf, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.017 · Cited by 118
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02543 · Cited by 118
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
Klobuch, S., Seijkens, T. T. P., Schumacher, T. N., & Haanen, J. B. A. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00848-w · Cited by 118
CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells
Maurice, N. J., McElrath, M. J., Andersen-Nissen, E., Frahm, N., & Prlic, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12980-2 · Cited by 117
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 117
Huang, D., Chen, X., Zeng, X., Lao, L., Li, J., Xing, Y., Lu, Y., Ouyang, Q., Chen, J., Yang, L., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00939-9 · Cited by 117
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
Ramakrishnan, R., Huang, C., Cho, H.-I., Lloyd, M. C., Johnson, J., Ren, X., Altiok, S., Sullivan, D. M., Weber, J. S., Celis, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2236 · Cited by 116
Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS
Gratia, M., Rodero, M. P., Conrad, C., Samra, E. B., Maurin, M., Rice, G., Duffy, D., Revy, P., Petit, F., Dale, R. C., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181329 · Cited by 116
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
Zheng, Y.-M., Wang, Y., Zhou, L., Wan, J., Jiang, L., Song, D., Wei, C., Gao, C., Shi, G., Zhou, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202301928 · Cited by 116
Gmünder, H., Eck, H., & Dröge, W. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16263.x · Cited by 114
Buchan, S. L., Fallatah, M., Thirdborough, S. M., Taraban, V. Y., Rogel, A., Thomas, L. J., Penfold, C. A., He, L.-Z., Curran, M. A., Keler, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3057 · Cited by 114
Kim, D., Endo, A., Fang, F. G., Huang, K., Bao, X., Choi, H.-W., Majumder, U., Shen, Y., Mathieu, S. R., Zhu, X., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100068 · Cited by 113
Vergani, E., Guardo, L. D., Dugo, M., Rigoletto, S., Tragni, G., Ruggeri, R., Perrone, F., Tamborini, E., Gloghini, A., Arienti, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6599 · Cited by 111
Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients
Herrera, M., Berral-González, A., López-Cade, I., Galindo-Pumariño, C., Bueno-Fortes, S., Martín-Merino, M., Carrato, A., Ocaña, A., de la Pinta, C., López‐Alfonso, A., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01367-x · Cited by 111
Anker, J. F., Naseem, A. F., Mok, H., Schaeffer, A. J., Abdulkadir, S. A., & Thumbikat, P. (2018) · Nature Communications · doi:10.1038/s41467-018-03900-x · Cited by 110
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability
Rañoa, D. R. E., Widau, R. C., Mallon, S., Parekh, A. D., Nicolae, C. M., Huang, X., Bolt, M. J., Arina, A., Parry, R., Kron, S. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1972 · Cited by 108
Meng, J., Yang, X. F., Huang, J., Tuo, Z., Hu, Y., Liao, Z., Tian, Y., Deng, S., Deng, Y., Zhou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300517 · Cited by 108
Pimenta, E. M., & Barnes, B. J. (2014) · Cancers · doi:10.3390/cancers6020969 · Cited by 107
Fan, R., Chen, C., Mu, M., Chuan, D., Liu, H., Hou, H., Huang, J., Tong, A., Guo, G. F., & Xu, J. (2023) · ACS Nano · doi:10.1021/acsnano.2c12217 · Cited by 107
Steinberg, S. M., Shabaneh, T. B., Zhang, P., Martyanov, V., Li, Z., Malik, B. T., Wood, T. A., Boni, A., Molodtsov, A. K., Angeles, C. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1755 · Cited by 105
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Francica, P., & Rottenberg, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0612-8 · Cited by 105
ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer
Wang, S., Böhnert, V., Joseph, A. J., Sudaryo, V., Skariah, G. M., Swinderman, J. T., Yu, F. B., Subramanyam, V., Wolf, D. M., Lyu, X., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313693120 · Cited by 105
Microbes and Cancer: Friends or Faux?
Azevedo, M. M., Pina‐Vaz, C., & Baltazar, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093115 · Cited by 104
Ottensmeier, C. H. H., Perry, K. L., Harden, E. L., Stasakova, J., Jenei, V., Fleming, J. C., Wood, O., Woo, J., Woelk, C. H., Thomas, G. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3121 · Cited by 103
Chung, C., Lin, C., Chen, C., Hsueh, C., Chang, Y., Wang, C., Chu, P., Tai, S., & Yang, M. (2023) · Advanced Science · doi:10.1002/advs.202204514 · Cited by 103
He, M., He, Q., Cai, X., Liu, J., Deng, H., Li, F., Zhong, R., Lu, Y. H., Peng, H., Wu, X., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005539 · Cited by 103
Chesney, J. A., Puzanov, I. J., Collichio, F. A., Singh, P. P., Milhem, M. M., Glaspy, J. A., Hamid, O., Ross, M. I., Friedlander, P. A., Garbe, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006270 · Cited by 103
Drew, Y., Kim, J., Penson, R. T., O’Malley, D. M., Parkinson, C., Roxburgh, P., Plummer, R., Im, S., Imbimbo, M., Ferguson, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2249 · Cited by 103
Ochs, K., Sahm, F., Opitz, C. A., Lanz, T. V., Oezen, I., Couraud, P., von Deimling, A., Wick, W., & Platten, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.09.011 · Cited by 101
CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer
Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X.-H., Yang, X., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005869 · Cited by 101
Hombach, A. A., Geumann, U., Günther, C., Hermann, F. G., & Abken, H. (2020) · Cells · doi:10.3390/cells9040873 · Cited by 101
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Lu, D., Chen, Y., Jiang, M., Wang, J., Li, Y., Ma, K., Sun, W., Zheng, X., Qi, J., Jin, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42010-1 · Cited by 101
Self-citationMetabolism-regulated ferroptosis in cancer progression and therapy
Ye, L., Wen, X., Qin, J., Zhang, X., Wang, Y., Wang, Z., Zhou, T., Di, Y., & He, W. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06584-y · Cited by 101
Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00748 · Cited by 99
Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., Noguchi, T., Arthur, C. D., Meng, W., Alspach, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.003 · Cited by 98
Activation of the STING Adaptor Attenuates Experimental Autoimmune Encephalitis
Lemos, H. D. P., Huang, L., Chandler, P., Mohamed, E. T., de Souza, G. R., Li, L., Pacholczyk, G. A., Barber, G. N., Hayakawa, Y., Munn, D. H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303258 · Cited by 97
Das, M., Shen, L., Liu, Q., Goodwin, T. J., & Huang, L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.012 · Cited by 97
Zhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., Ye, Y., Jin, G., & Zhang, H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00066-3 · Cited by 97
Ling, Y., Zhong, J., Weng, Z., Lin, G., Liu, C., Pan, C., Yang, H., Wei, X., Xie, X., Wei, X., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1074 · Cited by 97
Im, S. J., Obeng, R. C., Nasti, T. H., McManus, D. T., Kamphorst, A. O., Gunisetty, S., Prokhnevska, N., Carlisle, J. W., Yu, K., Sica, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221985120 · Cited by 97
CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
Goltz, D., Gevensleben, H., Vogt, T. J., Dietrich, J., Golletz, C., Bootz, F., Kristiansen, G., Landsberg, J., & Dietrich, D. (2018) · JCI Insight · doi:10.1172/jci.insight.96793 · Cited by 96
Sun, J. T., Sun, J., Song, B., Zhang, L., Shao, Q., Liu, Y., Yuan, D., Zhang, Y., & Qu, X. (2016) · Scientific Reports · doi:10.1038/srep35855 · Cited by 95
Qorraj, M., Bruns, H., Böttcher, M., Weigand, L., Saul, D., Mackensen, A., Jitschin, R., & Mougiakakos, D. (2017) · Leukemia · doi:10.1038/leu.2016.214 · Cited by 94
Immature natural killer cells promote progression of triple-negative breast cancer
Thacker, G., Henry, S., Nandi, A., Debnath, R., Singh, S., Nayak, A., Susnik, B., Boone, M., Zhang, Q. H., Kesmodel, S. B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abl4414 · Cited by 94
Diab, A. K., Gogas, H. J., Sandhu, S. K., Long, G. V., Ascierto, P. A., Larkin, J., Sznol, M., Franke, F. A., Ciuleanu, T., Pereira, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00172 · Cited by 94
Jean, A. S., Swofford, C. A., Panteli, J. T., Brentzel, Z. J., & Forbes, N. S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.36 · Cited by 93
Escamilla-Tilch, M., Filio‐Rodríguez, G., García‐Rocha, R., Mancilla‐Herrera, I., Mitchison, N. A., Ruiz‐Pacheco, J. A., Sánchez‐García, F. J., Sandoval‐Borrego, D., & Vázquez-Sánchez, E. A. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.58 · Cited by 93
Dudzinski, S. O., Cameron, B. D., Wang, J., Rathmell, J. C., Giorgio, T. D., & Kirschner, A. N. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0704-z · Cited by 93
Bockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy
Thakur, N., Thakur, S., Chatterjee, S., Das, J., & Sil, P. C. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.597806 · Cited by 92
Francica, B. J., Ghasemzadeh, A., Desbien, A. L., Theodros, D., Sivick, K. E., Reiner, G. L., Glickman, L. H., Marciscano, A. E. E., Sharabi, A. B., Leong, M. L. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0263 · Cited by 91
Shen, M., Smith, H. A., Wei, Y., Jiang, Y., Zhao, S., Wang, N., Rowicki, M., Tang, Y., Hang, X., Wu, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00280-y · Cited by 91
Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease
Mondanelli, G., Iacono, A., Allegrucci, M., Puccetti, P., & Grohmann, U. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01565 · Cited by 90
NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity
Guo, X., Tan, S., Wang, T., Sun, R., Li, S., Tian, P., Li, M., Wang, Y., Zhang, Y., Yan, Y., et al. (2022) · Hepatology · doi:10.1002/hep.32658 · Cited by 90
Ye, J., Yang, Y., Dong, W., Gao, Y., Meng, Y., Wang, H., Li, L., Jin, J., Ji, M., Xia, X., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s207589 · Cited by 89
PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide
Zhao, T., Wei, T., Guo, J., Wang, Y., Shi, X., Guo, S. J., Jia, X., Jia, H., & Feng, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1418-3 · Cited by 88
IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development
Li, A., Herbst, R. H., Canner, D. A., Schenkel, J. M., Smith, O. C. G., Kim, J. Y., Hillman, M., Bhutkar, A. J., Cuoco, M. S., Rappazzo, C. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.120 · Cited by 88
Lifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 88
Mok, T. S. K., Lopes, G., Cho, B. C., Kowalski, D. M., Kasahara, K., Wu, Y.-L. L. C., de Castro, G., Turna, H. Z., Cristescu, R., Aurora-Garg, D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.011 · Cited by 88
Zhou, C., Hu, Y., Arkania, E., Kılıçkap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.004 · Cited by 88
Książkiewicz, M., Gottfried, E., Kreutz, M. P., Mack, M., Hofstaedter, F., & Kunz‐Schughart, L. A. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.05.019 · Cited by 86
Willan, J., Cleasby, A. J., Rodriguez, N. F., Stefani, F., Rinaldo, C., Pisciottani, A., Grant, E. K., Woodman, P. G., Bryant, H. E., & Ciani, B. (2019) · Oncogenesis · doi:10.1038/s41389-019-0136-0 · Cited by 86
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?
Deligne, C., & Midwood, K. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620773 · Cited by 86
Marijt, K. A., Sluijter, M., Blijleven, L., Tolmeijer, S. H., Scheeren, F. A., van der Burg, S. H., & van Hall, T. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0627-8 · Cited by 85
cGAS restricts colon cancer development by protecting intestinal barrier integrity
Hu, S., Fang, Y., Chen, X., Cheng, T., Zhao, M., Du, M., Li, T., Li, M., Zeng, Z., Wei, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105747118 · Cited by 85
Lian, J., & Luster, A. D. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.05.003 · Cited by 84
Kim, H., Sehgal, D. N., Kucaba, T. A., Ferguson, D. M., Griffith, T. S., & Panyam, J. (2018) · Nanoscale · doi:10.1039/c8nr07201a · Cited by 84
Sung, E.-S., Ko, M., Won, J., Jo, Y., Park, E. Y., Kim, H. J., Choi, E., Jung, U.-J., Jeon, J., Kim, Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.003 · Cited by 84
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy
Kim, Y. J., Sheu, K. M., Tsoi, J., Abril-Rodríguez, G., Medina, E., Grasso, C. S., Torrejon, D. Y., Champhekar, A. S., Litchfield, K., Swanton, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145859 · Cited by 83
Mahadevan, K. K., LeBleu, V. S., Ramirez, E. V., Chen, Y., Li, B., Sockwell, A. M., Gagea, M., Sugimoto, H., Sthanam, L. K., Tampe, D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.07.025 · Cited by 83
Self-citationFröhlich, A., Loick, S., Bawden, E., Fietz, S., Dietrich, J., Diekmann, E., Saavedra, G., Fröhlich, H., Niebel, D., Sirokay, J. D., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102647 · Cited by 82
Voissière, A., Gomez‐Roca, C., Chabaud, S., Rodriguez, C., Nkodia, A., Berthet, J., Montané, L., Bidaux, A.-S., Treilleux, I., Eberst, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.add1834 · Cited by 82
Tumor-Derived Vascular Pericytes Anergize Th Cells
Bose, A., Barik, S., Banerjee, S., Ghosh, T., Mallick, A., Majumdar, S. B., Goswami, K. K., Bhuniya, A., Banerjee, S., Baral, R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300280 · Cited by 81
Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells
Plebanek, M. P., Bhaumik, D., Bryce, P. J., & Thaxton, C. S. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0981 · Cited by 80
DNA sensing via the cGAS/STING pathway activates the immunoproteasome and adaptive T‐cell immunity
Wang, X., Zhang, H., Wang, Y., Bramasole, L., Guo, K., Mourtada, F., Meul, T., Hu, Q., Viteri, V., Kammerl, I. E., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022110597 · Cited by 80
Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
Connolly, K. A., Belt, B. A., Figueroa, N. M., Murthy, A., Patel, A. P., Kim, M., Lord, E. M., Linehan, D. C., & Gerber, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13287 · Cited by 79
Chen, Y., Xu, L., Tang, T.-W., Chen, C.-H., Zheng, Q.-H., Liu, T., Mou, C., Wu, C.-H., & Wu, S. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16728 · Cited by 79
Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy
Escobar, G., Tooley, K., Oliveras, J. P., Huang, L., Cheng, H.-N., Bookstaver, M. L., Edwards, C., Froimchuk, E., Xue, C., Mangani, D., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.001 · Cited by 79
Zhan, S., Liu, Z., Zhang, M., Guo, T., Quan, Q., Huang, L., Guo, L., Cao, L., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01466 · Cited by 78
Sum, E., Rapp, M., Fröbel, P., Clech, M. L., Dürr, H., Giusti, A. M., Perro, M., Speziale, D., Kunz, L., Menietti, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4001 · Cited by 77
Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells
Hong, J., Tobin, N. P., Rundqvist, H., Li, T., Lavergne, M., García-Ibáñez, Y., Qin, H., Paulsson, J., Zeitelhofer, M., Adzemovic, M. Z., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv209 · Cited by 75
Wörmann, S. M., Zhang, A. X. W., Thege, F. I., Cowan, R. W., Rupani, D. N., Wang, R., Manning, S. L., Gates, C., Wu, W.-S., Levin-Klein, R., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00268-8 · Cited by 75
Zhao, Y., Ma, Y., Zang, A., Cheng, Y., Zhang, Y., Wang, X., Chen, Z., Qu, S., He, J., Chen, C., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01445-1 · Cited by 75
Yamauchi, M., Gibbons, D. L., Zong, C. C., Fradette, J. J., Bota‐Rabassedas, N., & Kurie, J. M. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.05.001 · Cited by 73
Hegewisch‐Becker, S., Mendez, G. A., Chao, J., Němeček, R., Feeney, K., Cutsem, E. V., Al‐Batran, S., Mansoor, W., Maisey, N. R., Pazo-Cid, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01636 · Cited by 73
Bryce, S. A., Wilson, R. A. M., Tiplady, E. M., Asquith, D. L., Bromley, S. K., Luster, A. D., Graham, G. J., & Nibbs, R. J. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501542 · Cited by 71
Promising targets based on pattern recognition receptors for cancer immunotherapy
Bai, L., Li, W., Zheng, W., Xu, D., Chen, N., & Cui, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105017 · Cited by 71
Intravesical In Situ Immunostimulatory Gel for Triple Therapy of Bladder Cancer
Guo, P., Wang, L., Shang, W., Chen, J., Chen, Z., Xiong, F., Wang, Z., Tong, Z., Wang, K., Yang, L. M., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c15176 · Cited by 71
Zheng, Q., Wang, Q., Wang, S., Wu, J., Gao, Q., & Liu, W. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.06.019 · Cited by 70
Johann, P.-D., Vaegler, M., Gieseke, F., Mang, P., Armeanu–Ebinger, S., Kluba, T., Handgretinger, R., & Müller, I. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-501 · Cited by 70
Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
Fridman, W. H., Sibéril, S., Pupier, G., Soussan, S., & Sautès‐Fridman, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101703 · Cited by 70
IGSF8 is an innate immune checkpoint and cancer immunotherapy target
Li, Y., Wu, X., Sheng, C., Liu, H., Liu, H., Tang, Y., Liu, C., Ding, Q., Xie, B., Xiao, X., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.039 · Cited by 70
Kato, K., Doki, Y., Ogata, T., Motoyama, S., Kawakami, H., Ueno, M., Kojima, T., Shirakawa, Y., Okada, M., Ishihara, R., et al. (2022) · Esophagus · doi:10.1007/s10388-022-00970-1 · Cited by 69
Overman, M., Gelsomino, F., Aglietta, M., Wong, M., Limón-Mirón, M. L., Leonard, G., García-Alfonso, P., Hill, A., Gracián, A. C., Cutsem, E. V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008689 · Cited by 69
Qamra, A., Xing, M., Padmanabhan, N., Kwok, J. J. T., Zhang, S., Xu, C., Leong, Y. S., Lim, A. P. L., Tang, Q., Ooi, W. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1022 · Cited by 68
Borràs, D. M., Verbandt, S., Ausserhofer, M., Sturm, G., Lim, J., Verge, G. A., Vanmeerbeek, I., Laureano, R. S., Govaerts, J., Sprooten, J., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00605-4 · Cited by 67
Growing tumors induce a local STING dependent Type I IFN response in dendritic cells
Andzinski, L., Spanier, J., Kasnitz, N., Kröger, A., Jin, L., Brinkmann, M. M., Kalinke, U., Weiß, S., Jabłońska, J., & Lienenklaus, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30159 · Cited by 67
Wieland, A., Kamphorst, A. O., Adsay, V. N., Masor, J. J., Sarmiento, J. M., Nasti, T. H., Darko, S. W., Douek, D. C., Xue, Y., Curran, W. J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2228-7 · Cited by 67
van Elssen, C. H. M. J., Vanderlocht, J., Oth, T., Senden-Gijsbers, B. L. M. G., Germeraad, W. T. V., & Bos, G. M. J. (2011) · Blood · doi:10.1182/blood-2010-09-307835 · Cited by 66
Zhang, Q., Hou, X., Evans, B. J., VanBlaricom, J. L., Weroha, S. J., & Cliby, W. A. (2018) · Cancers · doi:10.3390/cancers10080260 · Cited by 65
p53 Promotes Ferroptosis in Macrophages Treated with Fe3O4 Nanoparticles
Wu, C., zhang, B., Shen, Z., Sun, F., Lu, Y., Yuan, L., zhang, G., wang, Z., & Shi, H. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c00707 · Cited by 65
Self-citationPark, W., Gordon, A. C., Cho, S., Huang, X., Harris, K. R., Larson, A. C., & Kim, D. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b02258 · Cited by 64
Takeyama, Y., Kato, M., Tamada, S., Azuma, Y., Shimizu, Y., Iguchi, T., Yamasaki, T., Gi, M., Wanibuchi, H., & Nakatani, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.013 · Cited by 64
Kato, K., Doki, Y., Chau, I., Xu, J., Wyrwicz, L. S., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C., Adenis, A., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7235 · Cited by 64
Tang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12546 · Cited by 64
Ellem, S. J., Taylor, R. A., Furic, L., Larsson, O. S., Frydenberg, M., Pook, D. W., Pedersen, J., Cawsey, B., Trotta, A. P., Need, E. F., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4386 · Cited by 63
Montesinos, J. J., Mora‐García, M. D. L., Mayani, H., Figueroa, E. F., García‐Rocha, R., Fajardo-Orduña, G. R., Castro-Manrreza, M. E., Weiss‐Steider, B., & Monroy, A. (2013) · Stem Cells and Development · doi:10.1089/scd.2013.0084 · Cited by 63
Wang, K., Chen, Q., Liu, N., Zhang, J., & Pan, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.024 · Cited by 63
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
Chang, A. E., Golob, J. L., Schmidt, T. M., Peltier, D. C., Lao, C. D., & Tewari, M. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.02.005 · Cited by 62
Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer
Femel, J., Huijbers, E. J. M., Saupe, F., Cedervall, J., Zhang, L., Roswall, P., Larsson, E., Olofsson, H., Pietras, K., Dimberg, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2628 · Cited by 62
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI
Deng, L., Stafford, J. H., Liu, S.-C., Chernikova, S. B., Merchant, M. J., Recht, L. D., & Brown, J. M. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.010 · Cited by 62
Minnie, S. A., Waltner, O. G., Zhang, P., Takahashi, S., Nemychenkov, N. S., Ensbey, K. S., Schmidt, C. R., Legg, S. R. W., Comstock, M., Boiko, J. R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adg1094 · Cited by 62
Sundar, R., Huang, K. K., Qamra, A., Kim, K.-M., Kim, S. T., Kang, W. K., Tan, A., Lee, J., & Tan, P. B. O. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy550 · Cited by 61
Tan, L., Han, S., Ding, S., Xiao, W., Ding, Y., Li, Q., Wang, C., & Gong, W. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s128032 · Cited by 60
Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome
Guerra, D. A. P., Paiva, A. E., Sena, I. F. G., de Azevedo, P. O., da Silva, W. N., Mintz, A., & Birbrair, A. (2018) · Angiogenesis · doi:10.1007/s10456-018-9621-x · Cited by 60
Kolesnikoff, N., Chen, C.-H., & Samuel, M. S. (2022) · Clinical Science · doi:10.1042/cs20210679 · Cited by 60
Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy
Hashimoto, M., Ramalingam, S. S., & Ahmed, R. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.008 · Cited by 58
Zhang, Y., Xiang, C., Wang, Y., Duan, Y., Liu, C., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21328 · Cited by 57
Rafat, M., Aguilera, T. A., Vilalta, M., Bronsart, L. L., Soto, L. A. C., von Eyben, R., Golla, M. A., Ahrari, Y., Melemenidis, S., Afghahi, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3623 · Cited by 57
Wu, C., Muroski, M. E., Miska, J. M., Lee-Chang, C., Shen, Y., Rashidi, A., Zhang, P., Xiao, T., Han, Y., Lopez‐Rosas, A., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.11.015 · Cited by 56
Pereira, B., Lister, N. L., Hashimoto, K., Teng, L., Flandes‐Iparraguirre, M., Eder, A., Sánchez‐Herrero, A., Niranjan, B., Frydenberg, M., Papargiris, M., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.030 · Cited by 56
Giacopelli, B., Zhao, Q., Ruppert, A. S., Agyeman, A., Weigel, C., Wu, Y.-Z., Gerber, M. M., Rabe, K. G., Larson, M. C., Lu, J., et al. (2019) · Blood · doi:10.1182/blood.2019000490 · Cited by 56
Nanomaterials for modulating innate immune cells in cancer immunotherapy
Le, Q., Yang, G., Wu, Y., Jang, H. W., Shokouhimehr, M., & Oh, Y. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.07.003 · Cited by 55
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects
Wang, S., Wang, J., Xia, Y. X., Zhang, L., Jiang, Y., Liu, M., Gao, Q., & Zhang, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04938-w · Cited by 55
Old Dogs, New Tricks: Monogenic Autoinflammatory Disease Unleashed
Stoffels, M., & Kastner, D. L. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025334 · Cited by 54
Methylation of immune synapse genes modulates tumor immunogenicity
Berglund, A., Mills, M. N., Putney, R. M., Hamaidi, I., Mulé, J. J., & Kim, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131234 · Cited by 54
Mechanisms of chromatin-based epigenetic inheritance
Du, W., Shi, G., Shan, C., Li, Z., Zhu, B., Jia, S., Li, Q., & Zhang, Z. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2120-1 · Cited by 54
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 53
Tumor endothelial cell‐induced CD8+ T‐cell exhaustion via GPNMB in hepatocellular carcinoma
Sakano, Y., Noda, T., Kobayashi, S., Sasaki, K., Iwagami, Y., Yamada, D., Tomimaru, Y., Akita, H., Gotoh, K., Takahashi, H., et al. (2022) · Cancer Science · doi:10.1111/cas.15331 · Cited by 52
Meraz, I. M., Majidi, M., Cao, X. X., Lin, H. Y., Li, L., Wang, J., Baladandayuthapani, V., Rice, D. C., Sepesi, B., Ji, L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0273 · Cited by 51
TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy
Kim, H., Khanna, V., Kucaba, T. A., Zhang, W., Sehgal, D. N., Ferguson, D. M., Griffith, T. S., & Panyam, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00271 · Cited by 50
Davidsson, S., Carlsson, J., Greenberg, L., Wijkander, J., Söderquist, B., & Erlandsson, A. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01497-21 · Cited by 49
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Bhamidipati, D., & Subbiah, V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.002 · Cited by 49
Brower, B., McCoy, A. S., Ahmad, H., Eitman, C., Bowman, I. A., Rembisz, J., & Milowsky, M. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1326715 · Cited by 49
Gazdic, M., Marković, B. S., Jovicic, N. U., Misirkic-Marjanovic, M., Djonov, V., Jakovljevic, V. L., Arsenijević, N., Lukić, M. L., & Volarević, V. (2017) · Stem Cells International · doi:10.1155/2017/6294717 · Cited by 48
Cited by
Lee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy
Kim, H. C., Kim, H.-J., La, J., Park, W. H., Park, S. H., Kang, B. H., Kim, Y., & Lee, H. K. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115825 · Cited by 23
Metadata
- Authors
- Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-10-18
- Volume
- 9
- Issue
- 1
- Pages
- 274-274
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4403506731
- Cited by
- 682
- References
- 882
- FWCI
- 104.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.